Printer Friendly

COMPANY INFORMATION
Thallion Pharmaceuticals Inc. 7150 rue Alexander-Fleming Montréal, QC H4S 2C8 Tel: (514) 940-3600 Fax: (514) 228-3622 Contact Name Michael Singer Industry Biotechnology		Key Executives Allan Mandelzys, CEO Michael Singer, CFO Researches and develops pharmaceutical products in the areas of oncology and infectious disease.
FP ADVISOR COVERAGE Thallion Pharmaceuticals Inc. • FP Corporate Analyzer • FP Directory of Directors • FP Corporate Surveys • Ordering FP Products		TOP INDUSTRY PLAYERS Biotechnology Company Name Revenue ($000s)  Atrium Innovations Inc. 309,546 Angiotech Pharmaceuticals, Inc. 302,251 QLT Inc. 132,457 Oncothyreon Inc. 42,678 AEterna Zentaris Inc. 41,056 (Links are to Snapshots.)
FINANCIAL RATIOS AS OF FEB 8/10 Listed Close 52-wk High 52-wk Low IAD Latest Dividend Yield 60-mo Beta TSX/TLN $0.14 $0.32 $0.08 n.a. n.a. n.a. n.a. Avg 20-day Volume P/E 12-mo EPS EPS Date 1-yr Return 3-yr Return 5-yr Return Market Cap. (000s) 116,441 n.a. $-0.37 Aug. 31/09 n.a. n.a. n.a. $4,500
ANNUAL FINANCIALS Periods ended: 12m Nov. 30/081 12m Nov. 30/07 12m Nov. 30/06 $000s $000s $000s Operating revenue 163 2,053 227 Net income (15,108) (44,857) (6,804) Total assets 18,119 32,142 6,456 $ $ $ Earnings per share* (0.47) (1.80) (1.00) % % % Return on equity (69.49) (261.48) (79.43)   * Common 1 Results prior to July 22, 2009, pertain to (old) Thallion Pharmaceuticals Inc.
TRAILING 12-MONTH VALUES Periods ended: Aug. 31/09 Aug. 31/08 $000s $000s Operating revenue 163 26 Net income (11,885) (45,472) $ $ Earnings per share (0.36) (1.66)

COMPANY NEWS

Results for 'Thallion Pharmaceuticals Inc.' from past 30 days: No hits. (Links are to articles.)